Skip to content

Evolus EOLS Non-cash in-process research and development expense

Non-cash in-process research and development expense at other companies

UroGen Pharma logo
UroGen PharmaURGN
$0-100%
Erasca, Inc. logo
Erasca, Inc.ERAS
$150M
Immunome logo
ImmunomeIMNM
$9.01M+44.3%
UroGen Pharma logo
UroGen PharmaURGN
$0-100%
Erasca, Inc. logo
Erasca, Inc.ERAS
$150M
Campbell Soup logo
Campbell SoupCPB
$6M-82.9%

Other financials

Income statement

See full
Revenue$73.1M+6.7%
Gross profit$48.9M+4.8%
Operating income-$6.8M+54.9%
Net income-$10.7M+43.5%
EPS (diluted)-$0.16+46.7%

Balance sheet

See full
Cash & equivalents$49.8M-26.7%
Total debt$164.9M-4.1%
Total equity-$28.8M-336%
Total assets$220.6M+3.4%

Cash flow

See full
Operating cash flow-$10.0M+36.3%
CapEx$415.0K+30.1%
Free cash flow-$10.4M+35.0%

Valuation

See full
Market cap$470.86M-21.3%
Enterprise value$585.97M-16.6%
P/S1.6×-0.6×

Profitability

See full
Gross margin66.1%-2.4pp
Operating margin-13.7%-1.9pp
Net margin-14.4%-3.3pp
FCF margin-9.6%-3.6pp

Returns & leverage

See full
Return on equity-472.6%-1,534pp
Debt / equity22.2×
Current ratio-0.3×

Where this comes from

Reported directly by Evolus in its filing.

Tagged under the XBRL concept eols:NonCashInResearchAndDevelopmentInProcessExpenses.

The official record: Evolus’s 10-K, filed March 3, 2026, on SEC EDGAR. View the filing →

Ask your AI about Evolus's non-cash in-process research and development expense.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Evolus's non-cash in-process research and development expense?
Evolus (EOLS) reported non-cash in-process research and development expense of $0 in Q4 2025.
What does non-cash in-process research and development expense mean?
This metric captures the non-cash expense associated with the valuation of in-process research and development assets acquired through business combinations. It reflects the accounting treatment of R&D projects that have not yet reached technological feasibility at the time of acquisition. Tracking this helps investors understand the impact of acquisition accounting on reported earnings versus actual cash-based R&D investment.